Payment overview · 2025
General Payments
$465.17
24 reported records · 9 companies
Healthcare provider profile · identity verified
Benjamin C Schaffer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1245283902
Verified facts
What the public records show
CMS Open Payments records show Benjamin C Schaffer, MD received $465.17 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.73 | 44.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.03 | 17.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.86 | 9.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $37.27 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.38 | 5.7% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $23.23 | 5.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.68 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.17 | 3.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.82 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.17 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $186.31 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.57 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.38 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.86 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $37.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 623 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 113 |
| Losartan Potassium | Losartan Potassium | 257 | 71 |
| Lisinopril | Lisinopril | 216 | 62 |
| Metformin Hcl | Metformin Hcl | 216 | 61 |
| Omeprazole | Omeprazole | 200 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 38 |
| Gabapentin | Gabapentin | 141 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 44 |
| Alprazolam | Alprazolam | 133 | 50 |
| Allopurinol | Allopurinol | 126 | 34 |
| Jardiance | Empagliflozin | 126 | 28 |
| Ezetimibe | Ezetimibe | 120 | 33 |
| Montelukast Sodium | Montelukast Sodium | 109 | 26 |
| Simvastatin | Simvastatin | 100 | 31 |
| Famotidine | Famotidine | 98 | 30 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 91 | suppressed |
| Eliquis | Apixaban | 86 | 20 |
| Valsartan | Valsartan | 86 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 22 |
| Potassium Chloride | Potassium Chloride | 77 | 26 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 24 |
| Ozempic | Semaglutide | 71 | 18 |
| Synthroid | Levothyroxine Sodium | 61 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Valacyclovir | Valacyclovir Hcl | 59 | 13 |
| Carvedilol | Carvedilol | 58 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 14 |
| Lorazepam | Lorazepam | 57 | 15 |
| Trazodone Hcl | Trazodone Hcl | 57 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 18 |
| Mounjaro | Tirzepatide | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 38 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Furosemide | Furosemide | 34 | 16 |
| Diazepam | Diazepam | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Isentress | Raltegravir Potassium | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $465.17 · 24 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, DOVATO, FARXIGA, INGREZZA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error